Repligen | RGEN - Gross Profit On Sales

Stock Price
142.18
Daily Change
2.52 1.80%
Monthly
-15.89%
Yearly
-8.89%
Q1 Forecast
144.77

Repligen reported $100.52M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Agilent USD 990M 102M Sep/2025
Align Technology USD 683.59M 44.39M Dec/2025
Bio Techne USD 191.28M 3.16M Dec/2025
BioMarin Pharmaceutical USD 631.2M 39.27M Sep/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Bruker USD 379.4M 21.5M Sep/2025
Charles River Laboratories USD 311.39M 6.77M Sep/2025
Danaher USD 3.97B 443M Dec/2025
Dentsply International USD 441M 49M Sep/2025
Exact Sciences USD 583.93M 21.48M Sep/2025
General Electric Aerospace USD 3.8B 118M Dec/2025
Henry Schein USD 1.03B 74M Sep/2025
Illumina USD 759M 26M Dec/2025
IQVIA Holdings USD 1.12B 32M Dec/2025
Mettler Toledo International USD 675.44M 65.98M Dec/2025
Myriad Genetics USD 143.8M 8M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Repligen USD 100.52M 9.37M Sep/2025
Revvity USD 374.6M 17.95M Sep/2025
Standard Biotools USD 9.48M 1.15M Sep/2025
Thermo Fisher Scientific USD 4.64B 419M Dec/2025
Waters USD 459.99M 21.97M Sep/2025
West Pharmaceutical Services USD 294.3M 20.4M Sep/2025